What Factors Influence Minority Use of National Cancer Institute-Designated Cancer Centers?

被引:59
|
作者
Huang, Lyen C. [1 ]
Ma, Yifei [1 ,2 ]
Ngo, Justine V. [1 ]
Rhoads, Kim F. [1 ,2 ]
机构
[1] Stanford Univ, Sect Colon & Rectal Surg, Dept Surg, Sch Med, Stanford, CA 93405 USA
[2] Stanford Canc Inst, Canc Prevent & Control Program, Stanford, CA USA
基金
美国国家卫生研究院;
关键词
health care disparities; colorectal cancer; National Cancer Institute-designated cancer centers; socioeconomic factors; access to care; insurance coverage; LYMPH-NODE EVALUATION; COLORECTAL-CANCER; RACIAL DISPARITIES; UNITED-STATES; HEALTH DISPARITIES; TRAVEL-TIME; MORTALITY; HOSPITALS; CARE; QUALITY;
D O I
10.1002/cncr.28413
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
BACKGROUNDNational Cancer Institute (NCI) cancer centers provide high-quality care and are associated with better outcomes. However, racial and ethnic minority populations tend not to use these settings. The current study sought to understand what factors influence minority use of NCI cancer centers. METHODSA data set containing California Cancer Registry (CCR) data linked to patient discharge abstracts identified all patients with colorectal cancer (CRC) who were treated from 1996 through 2006. Multivariable models were generated to predict the use of NCI settings by race. Geographic proximity to an NCI center and patient sociodemographic and clinical characteristics were assessed. RESULTSApproximately 5% of all identified patients with CRC (n=79,231) were treated in NCI settings. The median travel distance for treatment for all patients in all hospitals was 5 miles. A higher percentage of minorities lived near an NCI cancer center compared with whites. A baseline multivariable model predicting use showed a negative association between Hispanic ethnicity and NCI center use (odds ratio, 0.71; 95% confidence interval, 0.64-0.79). Asian/Pacific Islander patients were more likely to use NCI centers (odds ratio, 1.41; 95% confidence interval, 1.28-1.54). There was no difference in use noted among black patients. Increasing living distance from an NCI cancer center was found to be predictive of lower odds of use for all populations. Medicare and Medicaid insurance statuses were positively associated with NCI center use. Neighborhood-level education was found to be a more powerful predictor of NCI use than poverty or unemployment. CONCLUSIONSSelect minority groups underuse NCI cancer centers for CRC treatment. Sociodemographic factors and proximity to NCI centers are important predictors of use. Interventions to address these factors may improve minority attendance to NCI cancer centers for care. Cancer 2014;120:399-407. (c) 2013 American Cancer Society.
引用
收藏
页码:399 / 407
页数:9
相关论文
共 50 条
  • [41] A survey of National Cancer Institute-designated comprehensive cancer centers' oral health supportive care practices and resources in the USA
    Epstein, Joel B.
    Parker, Ira R.
    Epstein, Matthew S.
    Gupta, Anurag
    Kutis, Susan
    Witkowski, Daniela M.
    SUPPORTIVE CARE IN CANCER, 2007, 15 (04) : 357 - 362
  • [42] The Impact of the COVID-19 Pandemic on Tobacco Treatment Program Implementation at National Cancer Institute-Designated Cancer Centers
    Hohl, Sarah D.
    Shoenbill, Kimberly A.
    Taylor, Kathryn L.
    Minion, Mara
    Bates-Pappas, Gleneara E.
    Hayes, Rashelle B.
    Nolan, Margaret B.
    Simmons, Vani N.
    Steinberg, Michael B.
    Park, Elyse R.
    Ashing, Kimlin
    Beneventi, Diane
    Cox, Lisa Sanderson
    Goldstein, Adam O.
    King, Andrea
    Kotsen, Chris
    Presant, Cary A.
    Sherman, Scott E.
    Sheffer, Christine E.
    Warren, Graham W.
    Adsit, Robert T.
    Bird, Jennifer E.
    D'Angelo, Heather
    Fiore, Michael C.
    Nguyen, Claire Van Thanh
    Pauk, Danielle
    Rolland, Betsy
    Rigotti, Nancy A.
    NICOTINE & TOBACCO RESEARCH, 2023, 25 (02) : 345 - 349
  • [43] Management of Occult Primary Breast Cancer at a National Cancer Institute-Designated Comprehensive Cancer Center
    Fayanju, Oluwadamilola
    Jeffe, Donna
    Margenthaler, Julie
    ANNALS OF SURGICAL ONCOLOGY, 2013, 20 : 40 - 40
  • [44] Differences in Patients, Surgical Complexity, and Outcomes After Cancer Surgery at National Cancer Institute-designated Cancer Centers Compared to Other Hospitals
    Merkow, Ryan P.
    Bentrem, David J.
    Chung, Jeanette W.
    Paruch, Jennifer L.
    Ko, Clifford Y.
    Bilimoria, Karl Y.
    MEDICAL CARE, 2013, 51 (07) : 606 - 613
  • [45] Tobacco Use Treatment at the US National Cancer Institute's Designated Cancer Centers
    Goldstein, Adam O.
    Ripley-Moffitt, Carol E.
    Pathman, Donald E.
    Patsakham, Katharine M.
    NICOTINE & TOBACCO RESEARCH, 2013, 15 (01) : 52 - 58
  • [46] Factors associated with biomedical research participation within community-based samples across 3 National Cancer Institute-designated cancer centers
    Barrett, Nadine J.
    Rodriguez, Elisa M.
    Iachan, Ronaldo
    Hyslop, Terry
    Ingraham, Kearston L.
    Le, Gem M.
    Martin, Kelly
    Haring, Rodney C.
    Rivadeneira, Natalie A.
    Erwin, Deborah O.
    Fish, Laura J.
    Middleton, Deidre
    Hiatt, Robert A.
    Patierno, Steven R.
    Sarkar, Urmimala
    Gage-Bouchard, Elizabeth A.
    CANCER, 2020, 126 (05) : 1077 - 1089
  • [47] Classical Hematology Referrals at an National Cancer Institute-Designated Cancer Center: Lessons Learned
    West, Chase V.
    Butler, Matthew J.
    Kaur, Supreet
    Bowhay-Carnes, Elizabeth
    Karnad, Anand B.
    JCO ONCOLOGY PRACTICE, 2024, 20 (01)
  • [48] The availability/accessibility gap of palliative care and supportive care services at 40 National Cancer Institute-designated cancer centers.
    Hutchins, Kathryn
    Hamlyn, Geoffrey
    Johnston, Abby
    Thomas, Rishonda
    Tian, James
    Kamal, Arif
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (26)
  • [49] Masking Policies at National Cancer Institute-Designated Cancer Centers During Winter 2023 to 2024 COVID-19 Surge
    Hoerger, Michael
    Rivera, Dulce
    Mossman, Brenna
    Sherard, Birney
    Peyser, Tristen
    Alcorn, Taylor M.
    JAMA NETWORK OPEN, 2024, 7 (07)
  • [50] Price variability of pembrolizumab across US National Cancer Institute-designated Cancer Centers (NCICCs) from 2016-2021.
    Hussaini, S. M. Qasim
    Johnson, Jordan
    Chino, Fumiko
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (28) : 48 - 48